Karyopharm Therapeutics (KPTI) Stock Forecast, Price & News

Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions

Is Karyopharm Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Karyopharm Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KPTI, but not buy additional shares or sell existing shares.
View analyst ratings for Karyopharm Therapeutics or view top-rated stocks.

When is Karyopharm Therapeutics' next earnings date?

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Karyopharm Therapeutics.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Thursday, May, 5th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.10. During the same period last year, the business posted ($0.77) EPS.
View Karyopharm Therapeutics' earnings history.

What price target have analysts set for KPTI?

6 brokers have issued 1-year price targets for Karyopharm Therapeutics' stock. Their forecasts range from $6.00 to $22.00. On average, they anticipate Karyopharm Therapeutics' stock price to reach $11.57 in the next twelve months. This suggests a possible upside of 81.4% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Karyopharm Therapeutics' key executives?

Karyopharm Therapeutics' management team includes the following people:

• Mr. Richard A. Paulson M.B.A., Pres, CEO & Director (Age 55, Pay $1.27M)
• Dr. Sharon Shacham M.B.A., Ph.D., Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board (Age 52, Pay $766.54k)
• Dr. Michael Glen Kauffman M.D., Ph.D., Co-Founder & Sr. Clinical Advisor (Age 59, Pay $1.64M)
• Mr. Michael P. Mason CPA, M.B.A., Exec. VP, CFO & Treasurer (Age 47, Pay $692.39k) (LinkedIn Profile)
• Mr. Ran Frenkel R.Ph., RPh, Exec. VP & Chief Devel. Officer (Age 53, Pay $667.87k)
• Dr. Mansoor Raza Mirza M.D., Clinical Consultant, Member of Scientific Advisory Board & Independent Director (Age 61, Pay $146.14k)
• Mr. Cameron Peters, VP of Fin., Assistant Treasurer & Principal Accounting Officer (Age 62)
• Mr. Pierre S. Sayad M.S., Ph.D., VP of Global Medical & Scientific Affairs
• Ms. Elhan Webb C.F.A., Sr. VP of Investor Relations
• Mr. Michael J. Mano J.D., Sr. VP, Gen. Counsel & Sec. (Age 45)

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

Who are some of Karyopharm Therapeutics' key competitors?

Some companies that are related to Karyopharm Therapeutics include Sage Therapeutics (SAGE), Amphastar Pharmaceuticals (AMPH), Schrödinger (SDGR), Turning Point Therapeutics (TPTX), Emergent BioSolutions (EBS), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), HUTCHMED (HCM), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN) and Xenon Pharmaceuticals (XENE).
View all of KPTI's competitors.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

What is Karyopharm Therapeutics' stock symbol?

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (13.81%), BlackRock Inc. (9.98%), Palo Alto Investors LP (7.08%), Vanguard Group Inc. (4.99%), Rice Hall James & Associates LLC (1.69%) and Rice Hall James & Associates LLC (1.69%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Sharon Shacham, Stephen Mitchener and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics.

Which institutional investors are selling Karyopharm Therapeutics stock?

KPTI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Frontier Capital Management Co. LLC, Citigroup Inc., Group One Trading L.P., Simplex Trading LLC, Dupont Capital Management Corp, Allianz Asset Management GmbH, and Rhumbline Advisers. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Jatin Shah, Michael Kauffman, Michael Mason, Sharon Shacham, and Stephen Mitchener.
View insider buying and selling activity for Karyopharm Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Karyopharm Therapeutics stock?

KPTI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Acadian Asset Management LLC, Candriam Luxembourg S.C.A., UBS Group AG, Victory Capital Management Inc., Palo Alto Investors LP, and Renaissance Technologies LLC. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics or or view top insider-buying stocks.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karyopharm Therapeutics' stock price today?

One share of KPTI stock can currently be purchased for approximately $6.38.

How much money does Karyopharm Therapeutics make?

Karyopharm Therapeutics has a market capitalization of $506.69 million and generates $209.82 million in revenue each year. The company earns $-124.09 million in net income (profit) each year or ($1.470010) on an earnings per share basis.

How many employees does Karyopharm Therapeutics have?

Karyopharm Therapeutics employs 442 workers across the globe.

What is Karyopharm Therapeutics' official website?

The official website for Karyopharm Therapeutics is www.karyopharm.com.

How can I contact Karyopharm Therapeutics?

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at (617) 658-0600 or via email at [email protected].